Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02315131 · ClinicalTrials.gov registry record · Phase 1
Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Terminated
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT02315131 is a Phase 1 study that was terminated before completion, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 53 participants.
The verdict
NCT02315131, a Phase 1 study, was terminated before completion, sponsored by Teva Branded Pharmaceutical Products R&D.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV46017
Interventions
- DRUG Placebo
- DRUG TV46017
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2015-03 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02315131
The ClinicalTrials.gov registry entry for NCT02315131 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02315131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02315131 about?
NCT02315131 is a clinical study titled "Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017". The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV46017
What is the current status of trial NCT02315131?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2015-03. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02315131?
The interventions under investigation include: Placebo (DRUG), TV46017 (DRUG).
Who is sponsoring clinical trial NCT02315131?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.